Oxford Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Oxford Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-54,375	Closed	-$798K	–	925
2019 Q4	$798K	Buy	54,375 +18,402	+51%	+$256K	0.02%	994
2019 Q3	$480K	Sell	35,973 -10,601	-23%	-$169K	0.01%	1279
2019 Q2	$762K	Buy	+46,574	New	+$732K	0.02%	1099
2019 Q1	–	Sell	-10,586	Closed	-$144K	–	1878
2018 Q4	$144K	Buy	+10,586	New	+$197K	﹤0.01%	1602
2017 Q3	–	Sell	-70,753	Closed	-$1.13M	–	1651
2017 Q2	$1.13M	Buy	+70,753	New	+$989K	0.02%	851

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Oxford Asset Management's NTLA Position: Q1 2020 in Review

Oxford Asset Management sold out of Intellia Therapeutics (NTLA) in Q1 2020, closing a stake of 54,375 shares — an estimated $798K sold.

Oxford Asset Management first reported a position in NTLA in Q2 2017 and held it in 5 quarters. The position peaked at $1.13M in Q2 2017. 140 funds tracked by Wall St. Rank hold NTLA as of Q1 2020.

Oxford Asset Management reported no remaining Intellia Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 54,375 Intellia Therapeutics shares in Q1 2020, an estimated $798K.
Oxford Asset Management first reported a position in Intellia Therapeutics in Q2 2017 and held it in 5 quarters.
Oxford Asset Management's Intellia Therapeutics position peaked at $1.13M in Q2 2017.
140 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.